期刊文献+

免疫复合物型增效乙型肝炎疫苗鉴别试验方法的建立 被引量:1

Development of A Method for Identity Test on Immune Complex as Enhanced Hepatitis B Vaccine
原文传递
导出
摘要 目的建立免疫复合物型增效乙型肝炎疫苗鉴别试验方法。方法分别应用酸性缓冲液Gly-HCl、HAc-NaAc、Na2HPO4-CA、CA-NaCA和表面活性剂DEA-T处理免疫复合物型增效乙型肝炎疫苗,采用ELISA法检测处理后疫苗中的HBsAg和HBIG,筛选最佳缓冲液;对鉴别试验的反应条件(pH值、反应时间、反应温度)进行优化;并对鉴别试验的精密性进行验证。结果选择CA-NaCA缓冲液作为免疫复合物型增效乙型肝炎疫苗鉴别试验的样品处理缓冲液,其既具有解离抗原抗体复合物的作用,又能使铝佐剂与吸附的蛋白质解离;鉴别试验最适pH值为3.0,最佳反应温度为25℃,最佳反应时间为30 min;该鉴别试验方法精密性良好。结论 建立了免疫复合物型增效乙型肝炎疫苗鉴别试验方法,为该疫苗的检定方法提供了必要的补充。 Objective To develop a method for identity test on immune complex as enhanced hepatitis B(HB) vaccine.Methods The immune complex as enhanced HB vaccine was treated with acidic buffers Gly-HCl,HAc-NaAc,Na2HPO4-CA,CA-NaCA and surface active reagent DEA-T respectively,and determined for HBsAg and HBIG by ELISA,based on which the optimal buffer was screened.The condition for identity test,including pH value,time and temperature,was optimized.The precision of identity test was verified.Results CA-NaCA buffer was screened for treatment of samples in identity test on enhanced HB vaccine,which dissociated either antigen-antibody complex or aluminum adjuvant and the adsorbed protein.The optimal pH value,temperature and time for identity test were 3.0,25℃ and 30 min respectively.The developed method for identity test showed high precision.Conclusion A method for identity test on immune complex as enhanced HB vaccine was developed,which was a necessary supplement of determination of HB vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2011年第9期1094-1097,共4页 Chinese Journal of Biologicals
关键词 抗原抗体复合物 增效乙型肝炎疫苗 鉴别试验 Antigen-antibody complex Enhanced hepatitis B vaccine Identity test
  • 相关文献

参考文献6

  • 1卢觅佳,吴友苹,陈颖,王海彬,虞骥,夏丽娟,宋翼升,罗家立,宣尧仙.药源性循环免疫复合物检测方法的建立[J].中国药理学通报,2009,25(9):1248-1250. 被引量:2
  • 2Hellstrom U, Lindh M, Krogsgaard K, et al. Demonstration of an association between detection of IgG antibody reactivity towards the C-terminal region of the preS1 protein of hepatitis B virus and the capacity to respond to interferon therapy in chronic hepatitis B[J].J Gastroenterol Hepatol, 2008, 23 (5): 804-810.
  • 3陈悦,杨东亮,李方和,喻植群,郝连杰.免疫转印技术在分析流行性出血热患者血清循环免疫复合物组份中的应用[J].同济医科大学学报,1995,24(2):161-163. 被引量:2
  • 4Johnston CT, Wang SL, Hem SL. Measuring the surface area of a- luminum hydroxide adjuvant[J].J Pharm Sci, 2002, 91 (7): 1702-1706.
  • 5Yau KP, Schulze DG, Johnston CT, et al. Aluminum hydroxide adjuvant produced under constant reactant concentration [J]. J Phann Sci, 2006, 95 (8): 1822-1833.
  • 6Hansen B, Belfast M, Soung G, et al. Effect of the strength of ad- sorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response[J]. Vaccine, 2009, 27 (6): 888- 892.

二级参考文献7

  • 1孙妩弋,张玲玲,吴丽,汪倪萍,王华,岳莉,张运芳,魏伟.重组人白细胞介素-1受体拮抗剂对大鼠胶原性关节炎的治疗作用[J].中国药理学通报,2005,21(1):92-95. 被引量:9
  • 2吕秋军.生物技术药物免疫原性的评价及面临的挑战[J].中国新药杂志,2007,16(3):181-188. 被引量:24
  • 3Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics [ J ]. Trends Biotechnol ,2006 ,24 :274 - 80.
  • 4Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals [ J ]. Nephrol Dial Transplant ,2006,21 ( Suppl 5 ) :9 -12.
  • 5Liebe V,Bruckmann M,Fischer K G,et al. Biological relevance of anti recombinant hirudin antibodies-resuhs from in vitro and in vivo studies [ J ]. Semin Thromb Hemost,2002,28 (5) :483 - 90.
  • 6苏汉文,詹玲屏.免疫复合物的检测方法[M]//朱立平,陈学清.免疫学常用实验方法.北京:人民军医出版社,2000:148-9.
  • 7Huub S. Bioequivalence and the immunogenicity of biopharmaceuticals [ J ]. Nat Rev Drug Discov Volume,2002,1:457 - 62.

共引文献2

同被引文献7

  • 1Kubba AK,Taylor P,Graneek B,et al.Non-responders to hep-atitis B vaccination:a review[J].Commun Dis Public Health,2003,6(2):106-112.
  • 2Xu DZ,Huang KL,Zhao K,et al.Vaccination with recombinantHBsAg-HBIG complex in healthy adults[J].Vaccine,2005,23(20):2658-2664.
  • 3Nimmerjahn F,Ravetch JV.Fcgamma receptors as regulators ofimmune responses[J].Nat Rev Immunol,2008,8(1):34-47.
  • 4Wen YM.Antigen-antibody immunogenic complex:promisingnovel vaccines for microbial persistent infections[J].Expert OpinBiol Ther,2009,9(3):285-291.
  • 5Hendriksen CF.Replacement,reduction and refinement alterna-tives to animal use in vaccine potency measurement[J].ExpertRev Vaccines,2009,8(3):313-322.
  • 6Randall RE,Young DF.Humoral and cytotoxic T cell immune re-sponses to internal and external structural proteins of simian virus5 induced by immunization with solid matrix-antibody-antigen com-plexes[J].J Gen Virol,1988,69(Pt 10):2505-2516.
  • 7Wen YM,Yuan ZH,Yao X.Experimentaland clinical studies onhepatitis B surfaceantigen-antibody complex therapeutic vaccine//Denyer DV.Progress in hepatitis B research[M].New York:No-va Science Publishers Inc.,2007:203-216.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部